During hospitalization in the ICU, rehabilitation exercises were recognized as a crucial method for enhancing patients′ quality of life, and the volume of exercise was shown to significantly influence the effectiveness of rehabilitation for ICU patients. This article reviews the definition of exercise volume in the context of ICU patient rehabilitation, the current status of reporting, its correlation with patient outcomes, and the available measurement tools. The aim is to provide a foundational reference for quantitative research on exercise rehabilitation in ICUs within our country.

Objective:To investigate key genes and cellular communication involved in spinal cord injury (SCI) repair using transcriptome sequencing and single-cell sequencing analysis.Methods:Two transcriptome sequencing datasets related to SCI and one single-cell sequencing dataset were obtained from the Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) in the two transcriptome sequencing datasets were analyzed using the limma package in R, followed by cross-analysis to identify common DEGs. Functional enrichment analysis of DEGs was performed using the DAVID database for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. Hub genes in the protein-protein interaction (PPI) network were identified using the cytoHubba plugin in Cytoscape. Single-cell sequencing data were analyzed using the Seurat package in R. Principal Component Analysis (PCA) was applied for dimensionality reduction, and t-distributed Stochastic Neighbor Embedding (t-SNE) was used for visualization. Cellular communication between different cell groups was analyzed using the CellChat package.Results:Differential analysis of transcriptome sequencing data identified 98 common DEGs. GO and KEGG enrichment analysis highlighted biological processes such as wound healing, macrophage activation, and immune response-related cell activation. The PPI network predicted 10 hub genes: ITGAM, TGFB1, CCL2, ICAM1, CD44, FN1, TIMP1, TLR2, ITGB2, and LGALS3. Single-cell sequencing analysis identified six distinct cell populations, including astrocytes, neurons, and fibroblasts. Cellular communication analysis revealed key signaling pathways between cell subpopulations, including SPP1- (ITGAV+ITGB1), SPP1- (ITGA5+ITGB1), TNF-TNFRSF1A transmission pathway, etc.Conclusions:During SCI repair, astrocytes receive signals from fibroblasts, monocytes, and neurons via the SPP1 pathway, while astrocytes and neurons receive signals from monocytes through the TNF pathway. These findings provide critical insights into the molecular mechanisms underlying SCI repair and offer a foundation for future research.

ObjectiveTo analyze the factors influencing meropenem-related liver injury （MRLI） and to explore their clinical predictive value. MethodsA retrospective case-control study was conducted， and the Chinese Hospital Pharmacovigilance System （CHPS） was used to establish a retrieval scheme. A total of 1 625 hospitalized cases using meropenem from January 2018 to December 2022 were collected. Patients were divided into case group （n=62） and control group （n=1 563） based on the presence or absence of liver injury. Clinical data and laboratory indicators from both groups were collected and analyzed. The t-test was used for comparison of normally distributed continuous data between the two groups， while the Mann-Whitney U test was used for comparison of continuous data not conforming to a normal distribution. The chi-square test was used for comparison of categorical data between the two groups. A multivariate Logistic regression analysis was performed to identify the influencing factors for MRLI. A Logistic regression equation was established， and the predictive value of these factors was assessed using the receiver operating characteristic （ROC） curve. ResultsThe results of univariate analysis indicated that the rates of male patients， hypoproteinemia， shock， intensive care unit （ICU） admissions， sepsis， and liver， gallbladder， and cardiovascular diseases， the levels of alanine aminotransferase （ALT）， alkaline phosphatase （ALP）， gamma-glutamyl transpeptidase （GGT）， aspartate aminotransferase （AST）， creatinine （CREA）， and procalcitonin （PCT）， and the number of hospitalization days were significantly higher in the case group than in the control group （P<0.05）， and that the platelet levels in the case group were significantly lower than those in the control group （P<0.05）. The multivariate Logistic regression analysis showed that male sex （odds ratio ［OR］=2.080， 95% confidence interval ［CI］： 1.050 — 4.123， P=0.036）， admission to the ICU （OR=8.207， 95%CI： 4.094‍ ‍—‍ ‍16.453， P<0.001）， comorbidity with gallbladder disease （OR=8.240， 95%CI： 3.605‍ ‍—‍ ‍18.832， P<0.001）， ALP （OR=1.012， 95%CI： 1.004‍ ‍—‍ ‍1.019， P=0.004）， GGT （OR=1.010， 95%CI： 1.005‍ ‍—‍ ‍1.015， P<0.001）， and PLT （OR=0.997， 95%CI： 0.994‍ ‍—‍ ‍0.999， P=0.020） were the influential factors for MRLI. The areas under the ROC curve of ALP， GGT， and PLT were 0.589， 0.637， and 0.595， respectively， and the AUC of them combined was 0.837. ConclusionMale sex， ICU admission， comorbidity with gallbladder disease， increased ALP， increased GGT， and decreased PLT were influencing factors for MRLI， and a combination of factors has a better predictive value for the occurrence of MRLI.

Pristimerin, which is one of the compounds present in Celastraceae and Hippocrateaceae, has antitumor effects. However, its mechanism of action in esophageal squamous cell carcinoma (ESCC) remains unclear. This study aims to investigate the efficacy and mechanism of pristimerin on ESCC in vitro and in vivo. The inhibitory effect of pristimerin on cell growth was assessed using trypan blue exclusion and colony formation assays. Cell apoptosis was evaluated by flow cytometry. Gene and protein expressions were analyzed through quantitative reverse transcription-polymerase chain reaction (qRT-PCR), Western blotting, and immunohistochemistry. RNA sequencing (RNA-Seq) was employed to identify significantly differentially expressed genes (DEGs). Cell transfection and RNA interference assays were utilized to examine the role of key proteins in pristimerin?s effect. Xenograft models were established to evaluate the antitumor efficiency of pristimerin in vivo. Pristimerin inhibited cell growth and induced apoptosis in ESCC cells. Upregulation of Noxa was crucial for pristimerin-induced apoptosis. Pristimerin activated the Forkhead box O3a (FoxO3a) signaling pathway and triggered FoxO3a recruitment to the Noxa promoter, leading to Noxa transcription. Blocking FoxO3a reversed pristimerin-induced Noxa upregulation and cell apoptosis. Pristimerin treatment suppressed xenograft tumors in nude mice, but these effects were largely negated in Noxa-KO tumors. Furthermore, the chemosensitization effects of pristimerin in vitro and in vivo were mediated by Noxa. This study demonstrates that pristimerin exerts an antitumor effect on ESCC by inducing AKT/FoxO3a-mediated Noxa upregulation. These findings suggest that pristimerin may serve as a potent anticancer agent for ESCC treatment.
Forkhead Box Protein O3/genetics* ; Humans ; Apoptosis/drug effects* ; Esophageal Squamous Cell Carcinoma/physiopathology* ; Esophageal Neoplasms/physiopathology* ; Pentacyclic Triterpenes ; Animals ; Cell Line, Tumor ; Proto-Oncogene Proteins c-bcl-2/genetics* ; Mice ; Signal Transduction/drug effects* ; Mice, Nude ; Cell Proliferation/drug effects* ; Triterpenes/pharmacology* ; Xenograft Model Antitumor Assays ; Mice, Inbred BALB C ; Male ; Gene Expression Regulation, Neoplastic/drug effects*

Objective:To analyze the clinical phenotypes and genetic features of a child with developmental and epileptic encephalopathy due to compound heterozygous variants in the ALG14 gene, and to improve clinicians′ understanding of the ALG14 gene and its associated disorders. Methods:Clinical data of a child with developmental and epileptic encephalopathy caused by ALG14 gene variants, who visited Linyi People′s Hospital on September 9, 2019, were collected and followed up. Whole exome sequencing (WES) and Sanger sequencing were applied to genetically detect the child and her parents, SWISS-MODEL software was used to perform 3D modeling of proteins for the screened ALG14 gene variants, and the literature was reviewed to summarize the clinical phenotypes and genetic characteristics of patients associated with ALG14 gene. Results:The proband, a 17-year-old female, presented with focal seizures and generalized tonic-clonic seizures, generalized developmental delay, cranial magnetic resonance imaging showing no significant abnormalities, and video-electroencephalogram showing widespread low-amplitude fast rhythms. The WES results showed that the affected child carried compound heterozygous variants c.243A>G (p.Ile81Met) and c.103delG(p.Glu35SerfsTer7) (NM_144988) in the ALG14 gene, and Sanger sequencing validation showed that they were derived from her father and mother with normal clinical phenotype, respectively, and the above loci had not been reported domestically or internationally. 3D modeling revealed that the p.Ile81Met variant resulted in a change in the coding amino acid at position 81, and alteration of the stability and hydrophobicity of the protein, which may affect the protein function; the p.Glu35SerfsTer7 variant resulted in early truncation of the peptide chain, loss of a large number of amino acid fragments, and significant alteration of the protein structure. According to the American College of Medical Genetics and Genomics and the Association for Molecular Pathology, p.Ile81Met was a variant of undetermined clinical significance (PM2+PM3+PP3), and p.Glu35SerfsTer7 was a likely pathogenic variant (PVS1+PM2+PP3). A total of 5 papers were retrieved reporting 13 cases related to ALG14 gene variants (including the present case), 4 cases with pure heterozygous variants, 9 with compound heterozygous variants, involving 11 variant types, all inherited from the parents, of which 9 being missense variants, 1 being shifted code variant, and 1 being intronic deletion variant. The main clinical phenotypes included epileptic seizure (11/13), hypotonia (10/13), craniofacial malformations (8/13), growth disorders (3/13), and behavioral abnormalities (2/13). Conclusions:This article reports the first case of ALG14 gene related developmental and epileptic encephalopathy in a child at home and abroad, characterized by focal seizures, generalized tonic-clonic seizures, and global developmental delay. The compound heterozygous variants c.243A>G (p.Ile81Met) and c.103delG(p.Glu35SerfsTer7) may be the genetic cause of this child, enriching the clinical phenotype and variation spectrum related to this gene.

Objective:To investigate key genes and cellular communication involved in spinal cord injury (SCI) repair using transcriptome sequencing and single-cell sequencing analysis.Methods:Two transcriptome sequencing datasets related to SCI and one single-cell sequencing dataset were obtained from the Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) in the two transcriptome sequencing datasets were analyzed using the limma package in R, followed by cross-analysis to identify common DEGs. Functional enrichment analysis of DEGs was performed using the DAVID database for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. Hub genes in the protein-protein interaction (PPI) network were identified using the cytoHubba plugin in Cytoscape. Single-cell sequencing data were analyzed using the Seurat package in R. Principal Component Analysis (PCA) was applied for dimensionality reduction, and t-distributed Stochastic Neighbor Embedding (t-SNE) was used for visualization. Cellular communication between different cell groups was analyzed using the CellChat package.Results:Differential analysis of transcriptome sequencing data identified 98 common DEGs. GO and KEGG enrichment analysis highlighted biological processes such as wound healing, macrophage activation, and immune response-related cell activation. The PPI network predicted 10 hub genes: ITGAM, TGFB1, CCL2, ICAM1, CD44, FN1, TIMP1, TLR2, ITGB2, and LGALS3. Single-cell sequencing analysis identified six distinct cell populations, including astrocytes, neurons, and fibroblasts. Cellular communication analysis revealed key signaling pathways between cell subpopulations, including SPP1- (ITGAV+ITGB1), SPP1- (ITGA5+ITGB1), TNF-TNFRSF1A transmission pathway, etc.Conclusions:During SCI repair, astrocytes receive signals from fibroblasts, monocytes, and neurons via the SPP1 pathway, while astrocytes and neurons receive signals from monocytes through the TNF pathway. These findings provide critical insights into the molecular mechanisms underlying SCI repair and offer a foundation for future research.

Background: Epimedii Folium, first recorded in the Shennong’s Classic of Materia Medica (Shen Nong Ben Cao Jing), is a traditional Chinese medicine (TCM) known for its effects of “benefiting Qi and strengthening the heart.” Icariside II (ICS II) is one of the main active components of Epimedii Folium, possessing cardiovascular protective and anti-inflammatory properties. However, the potential mechanisms of ICS II on myocardial ischemia (MI) remain unclear. Objective: The aim of the study was to investigate the effects and preliminary molecular mechanisms of ICS II in treating isoproterenolinduced MI in rats. Methods: A rat model of MI was established by subcutaneous injection of isoproterenol. Electrocardiography, echocardiography, myocardial enzymes analysis, heart weight index, triphenyltetrazolium chloride staining, histopathology, TUNEL staining, RT-qPCR, and Western blot were employed to evaluate the effects and preliminary molecular mechanisms of ICS II on MI rats. Results: Pharmacodynamic studies suggested that ICS II inhibited ST-segment elevation in electrocardiograms, improved cardiac function, reduced heart weight index and myocardial enzyme levels, decreased myocardial infarct size, alleviated cardiac histological damage, and inhibited apoptosis, thereby exerting cardioprotective effects in MI rats. Further studies revealed that ICS II may partially inhibit the expression of NLRP3/Caspase-1 axis-related targets at both protein and mRNA levels. Conclusions: Our findings indicate that ICS II exerts anti-MI effects, and its preliminary molecular mechanisms may be related to inhibiting the activation of the NLRP3/Caspase-1 axis to alleviate inflammatory responses.

Background: Epimedii Folium, first recorded in the Shennong’s Classic of Materia Medica (Shen Nong Ben Cao Jing), is a traditional Chinese medicine (TCM) known for its effects of “benefiting Qi and strengthening the heart.” Icariside II (ICS II) is one of the main active components of Epimedii Folium, possessing cardiovascular protective and anti-inflammatory properties. However, the potential mechanisms of ICS II on myocardial ischemia (MI) remain unclear. Objective: The aim of the study was to investigate the effects and preliminary molecular mechanisms of ICS II in treating isoproterenolinduced MI in rats. Methods: A rat model of MI was established by subcutaneous injection of isoproterenol. Electrocardiography, echocardiography, myocardial enzymes analysis, heart weight index, triphenyltetrazolium chloride staining, histopathology, TUNEL staining, RT-qPCR, and Western blot were employed to evaluate the effects and preliminary molecular mechanisms of ICS II on MI rats. Results: Pharmacodynamic studies suggested that ICS II inhibited ST-segment elevation in electrocardiograms, improved cardiac function, reduced heart weight index and myocardial enzyme levels, decreased myocardial infarct size, alleviated cardiac histological damage, and inhibited apoptosis, thereby exerting cardioprotective effects in MI rats. Further studies revealed that ICS II may partially inhibit the expression of NLRP3/Caspase-1 axis-related targets at both protein and mRNA levels. Conclusions: Our findings indicate that ICS II exerts anti-MI effects, and its preliminary molecular mechanisms may be related to inhibiting the activation of the NLRP3/Caspase-1 axis to alleviate inflammatory responses.

Background: Epimedii Folium, first recorded in the Shennong’s Classic of Materia Medica (Shen Nong Ben Cao Jing), is a traditional Chinese medicine (TCM) known for its effects of “benefiting Qi and strengthening the heart.” Icariside II (ICS II) is one of the main active components of Epimedii Folium, possessing cardiovascular protective and anti-inflammatory properties. However, the potential mechanisms of ICS II on myocardial ischemia (MI) remain unclear. Objective: The aim of the study was to investigate the effects and preliminary molecular mechanisms of ICS II in treating isoproterenolinduced MI in rats. Methods: A rat model of MI was established by subcutaneous injection of isoproterenol. Electrocardiography, echocardiography, myocardial enzymes analysis, heart weight index, triphenyltetrazolium chloride staining, histopathology, TUNEL staining, RT-qPCR, and Western blot were employed to evaluate the effects and preliminary molecular mechanisms of ICS II on MI rats. Results: Pharmacodynamic studies suggested that ICS II inhibited ST-segment elevation in electrocardiograms, improved cardiac function, reduced heart weight index and myocardial enzyme levels, decreased myocardial infarct size, alleviated cardiac histological damage, and inhibited apoptosis, thereby exerting cardioprotective effects in MI rats. Further studies revealed that ICS II may partially inhibit the expression of NLRP3/Caspase-1 axis-related targets at both protein and mRNA levels. Conclusions: Our findings indicate that ICS II exerts anti-MI effects, and its preliminary molecular mechanisms may be related to inhibiting the activation of the NLRP3/Caspase-1 axis to alleviate inflammatory responses.